Cargando…
Natural products: a hope for glioblastoma patients
Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temo...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955138/ https://www.ncbi.nlm.nih.gov/pubmed/29774132 http://dx.doi.org/10.18632/oncotarget.25175 |
_version_ | 1783323651055026176 |
---|---|
author | Vengoji, Raghupathy Macha, Muzafar A. Batra, Surinder K. Shonka, Nicole A. |
author_facet | Vengoji, Raghupathy Macha, Muzafar A. Batra, Surinder K. Shonka, Nicole A. |
author_sort | Vengoji, Raghupathy |
collection | PubMed |
description | Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB). Cancer stem cells (CSCs) have intrinsic resistance to initial chemoradiation therapy (CRT) and acquire further resistance via deregulation of many signaling pathways. Due to the failure of classical chemotherapies and targeted drugs, research efforts focusing on the use of less toxic agents have increased. Interestingly, multiple natural compounds have shown antitumor and apoptotic effects in TMZ resistant and p53 mutant GBM cell lines and also displayed synergistic effects with TMZ. In this review, we have summarized the current literature on natural products or product analogs used to modulate the BBB permeability, induce cell death, eradicate CSCs and sensitize GBM to CRT. |
format | Online Article Text |
id | pubmed-5955138 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2018 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-59551382018-05-17 Natural products: a hope for glioblastoma patients Vengoji, Raghupathy Macha, Muzafar A. Batra, Surinder K. Shonka, Nicole A. Oncotarget Review Glioblastoma (GBM) is one of the most aggressive malignant tumors with an overall dismal survival averaging one year despite multimodality therapeutic interventions including surgery, radiotherapy and concomitant and adjuvant chemotherapy. Few drugs are FDA approved for GBM, and the addition of temozolomide (TMZ) to standard therapy increases the median survival by only 2.5 months. Targeted therapy appeared promising in in vitro monolayer cultures, but disappointed in preclinical and clinical trials, partly due to the poor penetration of drugs through the blood brain barrier (BBB). Cancer stem cells (CSCs) have intrinsic resistance to initial chemoradiation therapy (CRT) and acquire further resistance via deregulation of many signaling pathways. Due to the failure of classical chemotherapies and targeted drugs, research efforts focusing on the use of less toxic agents have increased. Interestingly, multiple natural compounds have shown antitumor and apoptotic effects in TMZ resistant and p53 mutant GBM cell lines and also displayed synergistic effects with TMZ. In this review, we have summarized the current literature on natural products or product analogs used to modulate the BBB permeability, induce cell death, eradicate CSCs and sensitize GBM to CRT. Impact Journals LLC 2018-04-24 /pmc/articles/PMC5955138/ /pubmed/29774132 http://dx.doi.org/10.18632/oncotarget.25175 Text en Copyright: © 2018 Vengoji et al. http://creativecommons.org/licenses/by/3.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0/) 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Review Vengoji, Raghupathy Macha, Muzafar A. Batra, Surinder K. Shonka, Nicole A. Natural products: a hope for glioblastoma patients |
title | Natural products: a hope for glioblastoma patients |
title_full | Natural products: a hope for glioblastoma patients |
title_fullStr | Natural products: a hope for glioblastoma patients |
title_full_unstemmed | Natural products: a hope for glioblastoma patients |
title_short | Natural products: a hope for glioblastoma patients |
title_sort | natural products: a hope for glioblastoma patients |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5955138/ https://www.ncbi.nlm.nih.gov/pubmed/29774132 http://dx.doi.org/10.18632/oncotarget.25175 |
work_keys_str_mv | AT vengojiraghupathy naturalproductsahopeforglioblastomapatients AT machamuzafara naturalproductsahopeforglioblastomapatients AT batrasurinderk naturalproductsahopeforglioblastomapatients AT shonkanicolea naturalproductsahopeforglioblastomapatients |